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ABSTRACT: 
Backgrounds: Medulloblastoma (MB) is the commonest brain malignancy in childhood with 
poor prognosis, because of its rapid aggressive growth and frequent occurrence. The current 
chemotherapeutic regimens for medulloblastoma patients involve a combination of lomustine, 
cisplatin,  carboplatin,  vincristine  or  cyclophosphamide,  which  have  distinct  short-  and 
long-term  side-effects.  It  is  therefore  in  urgent  need  to  explore  safer  and  more  effective 
adjuvant  approach(s).  Resveratrol,  a  polyphenol  rich  in  numerous  plants,  has  multiple 
biological activities including anticancer effects. Our previous data confirmed that resveratrol 
inhibited proliferation and induced differentiation and apoptosis of medulloblastoma cells. 
SIRT1 is a deacetylase of class III HDACs and the supposed molecular effecter of resveratrol. 
SIRT1 involves in aging prevention and cancer formation in a cell-context specific manner. 
Nevertheless,  the  datum  concerning  the  role(s)  of  SIRT1  in  formation  and  prognosis  of 
medulloblastoma is still missing. 
 
Objective:  The  present  study  aimed  to  address  the  expression  patterna  of  SIRT1  in 
medulloblastoma tissues and non-cancerous counterparts and to explore whether resveratrol 
exerts its anti-medulloblastoma effects via regulating SIRT1 expression and bioactivity.   
 
Methods: The expression of SIRT1 in medulloblastoma and non-cancerous counterparts was 
elucidated  by  immunohistochemical  ataining  (IHC).  To  clarify  the  function  of  SIRT1  in 
medulloblastomas, SIRT1 expression in UW228-3 medulloblastoma cells were suppressed by Functional Foods in Health and Disease 2013; 3(5):154-165                                                    Page 155 of 165 
RNA interference (RNAi). The influence of resveratrol in SIRT1 expressions in UW228-3 
cells  was  analyzed  by  reverse  transcription-polymerase  chain  reaction  (RT-PCR), 
immunocytochemistry (ICC) and Western blotting (WB). The catalytic activity of deacetylase 
SIRT1 was examined by measuring the acetylation of the main substrate p53. 
 
Results: IHC staining revealed that SIRT1 was expressed in 64.17% of MB tissues, which 
was higher than that in noncancerous cerebellum tissues (14.29%). The frequencies of SIRT1 
expression in the nodular MB (22.22%) with better prognosis is lower than that in anaplastic 
MB (79.07% ) and classic MB (60.29 %; P<0.05). The proliferation of UW228-3 cells was 
remarkably  suppressed  after  being  transfected  with  SIRT1  siRNA,  accompanied  with 
extensive cell death. The results of RT-PCR and WB showed that after 48 hours 100 M 
resveratrol  treatment,  SIRT1  expression  in  UW228-3  cells  was  down-regulated  at  both 
transcriptional and translational levels. However, resveratrol has no effect on the deacetylase 
activity of SIRT1. 
 
Conclusion:  The  above  findings  suggested  that  SIRT1  expression  is  corrected  with  the 
formation and prognosis of human MB. Resveratrol influences SIRT1 functioning in human 
MB cells through inhibiting SIRT1 expression rather than modulating its acetylation activity.   
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BACKGROUND: 
Medulloblastoma (MB) is the commonest brain tumor in childhood. Due to rapid growth, 
high invasiveness and frequent recurrence, the prognosis of MB is very poor. Although the 
therapy for MBs has been improved and the disease-free survival rates have been more or 
less increased, MB is still incurable for about 1/3 patients [1]. Moreover, prognosis is worse 
for patients less than 3 years old, due to inadequate degree of resection. As an important part 
of  therapy,  chemotherapy  can  reduce  risk  of  recurrence,  which  is  usually  fatal.  It  is 
noteworthiness that drugs widely used such as lomustine, cisplatin, cyclophosphamide etc, 
bring severe unwanted side-effects and cause long-term disability. Therefore, it is impending 
to find safer and more effective drugs or potentiators for clinical management of MBs.   
 
INTRODUCTION: 
Resveratrol (Res), a polyphenol rich in various plants, has multiple beneficial activities, such 
as extending lifespan and delaying the onset of diseases associated with aging. Since 1997 [2], 
the cancer preventive effects of Res have been extensively demonstrated [3-7]. It is, therefore, 
considered as an excellent candidate for potentiator of platinum treatment [8]. Difficulties of 
drug delivery across the blood-brain barrier and failure to eliminate cancer stem cells are 
believed to be the major causes of recurrences in children with MB [9]. It is worthy noted that 
Res can be transported across blood-brain barrier through simple diffusion [10]. Our group Functional Foods in Health and Disease 2013; 3(5):154-165                                                    Page 156 of 165 
demonstrated that Res could significantly inhibit the proliferation and induced differentiation 
and  apoptosis  of  MB  cells  [11].  For  this  reason,  we  tried  to  gain  insights  into  the 
mechanism(s) underlying the anti-medulloblastoma effects of resveratrol.   
SIRT1, the most studied member of Sirtuins family, has been demonstrated to play 
roles in various biological processes, such as cell growth, differentiation and apoptosis. There 
is considerable debate on the roles of SIRT1 in tumorigenesis. In some cancers, SIRT1 is a 
tumor  promoter  [12-14],  on  the  contrary,  in  other  cancers,  it  acts  as  a  tumor  suppressor 
[15-17]. So far, it is widely accepted that SIRT1 functions in a cell-tissue context specific 
manner. It has been reported that SIRT1 involves in the differentiation of neural progenitors 
[18-19] and involves in the formation of neural tumor [20]. Limited studies in MB showed 
that inhibition of SIRT1 expression can induce the apoptosis of DAOY and MED283 MB 
cells [21]. However, in vivo data about roles of SIRT1 in MBs is absent. Our current study 
aimed to address this issue.   
 
MATERIALS AND METHODS: 
Tissue collection and tissue microarray-based immunohistochemical staining 
With  the  consent  of  patients,  MB  tissues  blocks  were  collected  and  prepared  in  tissue 
microarrays as described previously [22]. Immunohistochemical staining/IHC was performed 
on the sections from microarray. Briefly, deparaffinizing and rehydrating the sections, then, 
retrieving the antigen. After blocked with normal serum, the sections were incubated with 
solution containing primary polyclonal SIRT1 antibody (1:200, Santa Cruz Biotechnology, 
Inc,  USA).  Then  the  sections  were  incubated  with  a  horseradish  peroxidase  conjugated 
secondary antibody, followed by development with diaminobenzidine and counter-staining 
with hematoxylin. Experienced pathology technicians reviewed and scored 10 separate fields 
for each slide. IHC staining was graded on a scale (Table.1) [23]. 
 
Table.1 IHC Scale for SIRT1 in different cerebellum tissues 
 
Scale  Positive staining in cells 
-  no   
+  <20%   
++  21~50% 
+++  >50% 
 
Cell culture and treatment: Human UW228-3 MB cells were incubated in DMEM medium 
supplemented with 10% fetal bovine serum and cultured in a incubator with 5% CO2 at 37C. 
The cells were sub-cultured and treated with siRNA sequences against SIRT1 (SIRT1 siRNA) 
and 100uMRes, respectively. Three independent SIRT1 siRNA and controls were designed Functional Foods in Health and Disease 2013; 3(5):154-165                                                    Page 157 of 165 
and  synthesized  by  Shanghai  GenePharma  Co.,  Ltd,  China.  Res  were  purchased  from 
Sigma-Aldrich.Co and resolved with DMSO and DMEM medium, respectively, to a stock 
concentration at 100mM.   
 
Evaluation of SIRT1 expression: In order to examine the influences of SIRT1 siRNA and 
Res on MB cells, RT-PCR, ICC and WB were conducted to measure the expression of SIRT1 
at transcriptional and translational levels. In RT-PCR, the primer sequences for Sirt1 are: 
5’-TCAGTGTCATGGTTCCTTTGC-3’  (upward)  and  5’-AATCTGCTCCTTTG 
CCACTCT-3’ (downward) (620bp). The reaction were performed according the condition in 
relate  article  [24].  The  primer  sequences  for  control  β-actin  are 
5’-GCATGGAGTCCTGTGGCAT-3’  (upward)  and  5’-CTAGAAGCATTTGCGG  TGG-3’ 
(downward) (326bp) [25]. In ICC, the polycolonal anti human SIRT1 antiboby was diluted at 
1:200 and then added on the coverslips beared with MB cells. WB analyses were performed 
according previous article [25]. Briefly, prepare lysate from cell culture and determine the 
protein concentration. Load equal amounts of protein into the wells of the SDS-PAGE gel, 
along  with  the  molecular  weight  markers.  Then  transfer  the  protein  from  the  gel  to  the 
nitrocellulose membrane. After blocking in the 5% blocking buffer in TBS, the membranes 
were staining with appropriate dilutions of primary antibody SIRT1 (1:800) and p53(acetyl 
K382) (1:500). Finally, incubate the membrane with solution containing secondary antibody 
and acquire image using techniques for chemiluminesence.   
 
Flow  cytometry  (FCM)  analysis:  To  determine  the  effects  of  SIRT1  silencing  on  cell 
proliferation, UW228-3 cells treated with or without SIRT1 siRNA were analyzed by FCM. 
The cells were detached with 0.25% trypsin, washed three times with phosphate buffered 
saline (PBS; pH7.4) and then fixed with 75% ethanol. The cell samples were re-suspended in 
0.5ml PBS and stained with propidium iodide (PI) in the darkness for 30 minutes. The DNA 
contents were measured by fluorescence-activated cell sorting/FACS on a Becton-Dickinson 
FACScan flow cytometry system and the data were analyzed using a Cellfit software (Becton, 
Dickinson and Company). 
 
Statistic analysis 
The discrepancy of SIRT1 expression in MB tissue and non-cancerous lesions were evaluated 
by non-parametric Kruskal-Wallis test (SPSS 11.5).   
 
RESULTS: 
Up-regulated SIRT1 expression in MB tissues     
The  expression  of  SIRT1  protein  were  detected  by  IHC  staining  in  4  tissue  microarrays 
containing 120 MBs and 7 tumor-surrounding noncancerous tissues. As shown in Table 2, the 
overall frequency of SIRT1 expression in cancerous tissues is 64.17% (77/120), which is 
higher than that (14.29%; 1/7) in noncancerous cerebellar tissues (P=0.009).   
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Table 2. Expression of SIRT1 in different cerebellum lesions 
Histology  Positive  rate 
(%) 
-      +          
≥++     
Noncancerous  1/7 (14.29)  6            1              0 
 
medulloblastoma 
Large 
cell 
34/43 
(79.07%)** 
9          19            15 
Classic  41/68 
(60.29%)** 
27        19            22 
Nodular  2/9 (22.22%)  7            1              1 
  * statistical significance (p<0.05) compared with noncancerous tissues. 
** statistical significance (p<0.05) compared with nodular medulloblastoma. 
 
Differential SIRT1 expression in three medulloblastoma subtypes   
MB tissues were classified into three morphological groups: large cell/anaplastic MB (n=43), 
classic MB (n=68) and nodular/demoplastic MB (n=9). Analysis of IHC data revealed that 
the positive rates of SIRT1 protein were different in the three subtypes (Table 2). Statistical 
analysis  revealed  that  the  frequencies  of  SIRT1  expression  in  the  anaplastic/large  cell 
(79.07%) and the classic MB (60.29%) have no statistical difference (P>0.05), but they are 
higher  than  that  of  the  nodular/demoplastic  (22.22%)  subtypes  (P<0.05).  According  to 
clinical reports [26-27], the patients with the nodular MB usually have better prognosis than 
the other two subtypes.   
 
SIRT1-specific RNAi caused growth inhibition and apoptosis   
To explore the role of SIRT1 in survival of MB cells and validate the conclusion of IHC, the 
viability was detected in MB cells treated with SIRT1 siRNA and mock siRNA. As first, the 
expression of SIRT1 was manipulated by introducing three SIRT1-siRNA candidates into 
UW228-3 cells, respectively (Table 3).     
 
Table 3   SIRT1 siRNA sequences (5’→ 3’) 
  sense  antisense 
1  GGAUGAAAGUGAAAUUGAA  UUCAAUUUCACUUUCAUCC 
2  AGCUGUUGGUCAAGACUAA  UUAGUCUUGACCAACAGCU 
3  GCAUGAUGUUUGUGUGCUA  UAGCACACAAACAUCAUGC 
Negative control  UUCUCCGAACGUGUCACGU  ACGUGACACGUUCGGAGAA 
Positive control (p53)  CUACUUCCUGAAAAACAACG  CGUUGUUUUCAGGAAGUAG 
 
The inhibitory influences were evaluated by RT-PCR and WB. The results revealed that 
the  SIRT1  siRNA  sequence-1  exhibited  better  inhibitory  effects  (about  80%)  on  SIRT1 
transcription and translation, in contrast, no SIRT1 down-regulation was observed in cells 
transfected with mock siRNA [Figure 1A]. The effects of SIRT1 siRNA on proliferation and Functional Foods in Health and Disease 2013; 3(5):154-165                                                    Page 159 of 165 
apoptosis were estimated in the cells treated with or without SIRT1 siRNA sequence-1 for 48 
hours. H&E staining and FCM assay revealed that the growth of the cells was suppressed and 
the apoptosis fractions and proportion of cell at G1 phage increased (Figure 1B).   
 
 
 
Figure 1.  Selective silencing of SIRT1 by specific siRNA transfection and its  biological 
effects on UW228-3 cells. 
 
A. RT-PCR and Western-blot evaluation of the effects of SIRT1 siRNA on SIRT1 expression 
at transcriptional and translational levels, which were both downregulated. B. H&E staining 
showed the decrease of cell number after silencing SIRT1, which was further comfirmed by 
the  FCM  analysis.  SIRT1  siRNA  induced  the  G1  arrest  and  appearance  of  the  peak  of 
apoptosis. 
 
Res suppressed expression but not activity of SIRT1 in MB cells: To clarify potential 
correlation  of  the  anti-MB  activity  of  Res  with  its  effects  on  SIRT1  expression,  SIRT1 
expression in UW228-3 MB cells with and without Res treatment. The results of RT-PCR, 
ICC  and  Western  blotting  reveal  that  the  expression  of  SIRT1  decreased  at  both 
transcriptional and translational level after Res treatment [Figure 2A, 2B]. As a deacetylase, 
SIRT1 can mediate lots of biological processes by deacetylating target proteins. SIRT1 can 
suppress  the pro-apoptotic activity of p53 by  removing the acetylated lysine residue and 
promote the survival of cancer cells [28-29]. Since Res is often referred as the activator of 
SIRT1 [30], the acetylating level of p53 at 382 lysine has been examined, which shows that 
the level of p53 (k 382) did not changed significantly after treated with 100uM Res for 48hrs.   
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Figure 2. The effects of Res on the function of SIRT1 in UW228-3 cells.   
A. The expression of SIRT1 at transcriptional and translation level were both decreased after treated with Res. 
But Res did not decrease the enzymatic activity of deacetylase SIRT1 as expected by measuring the acetylated 
p53, the main substrate of SIRT1. B. Similarly, ICC staining ascertained the diminished of SIRT1 protein. 
 
DISCUSSION: 
Sirtuins are found in all organisms and act as the critical regulators at the crossroads between 
cancer and aging [31,32]. SIRT1, a well understood member of Sirtuin family, modulates 
several cell signaling pathways in normal and malignant cells [33, 34]. It prevents cell aging 
and apoptosis  of normal  cells  [35, 36], while the data obtained from human cancers are 
controversial because this protein is considered as a tumor promoter in neuroblastomas as 
well as prostate and skin cancers [37-39], but as a tumor suppressor in colon and breast 
cancers [40, 41]. The conflicting data imply the cell type-related expression and functioning 
of SIRT1 in human malignancies [42]. It has been proven that SIRT1 is one of the major 
determinants of neural progenitor cell differentiation [43, 44]. MB is thought to originate 
from the primitive neuroectodermal cells. We speculated that SIRT1 might play certain role(s) 
in MB.   
Our in vivo data demonstrated that the overall frequency of SIRT1 expression in MB 
were higher than that in tumor-surrounding tissues. Furthermore, in three major MB subtypes, 
with different histological features, aggressiveness and the grades of differentiation, SIRT1 
proteins expressed differentially. The clinical data revealed that the classic MB and the large 
cell MB were less differentiated with rapid growth, resulting in unfavorable clinical outcome; 
in  contrast,  the  nodular  MB  were  surrounded  by  extensive  ﬁbrogenic  tissues  with  pale 
nodules  of  differentiating  neuroblasts;  consequently,  patients  with  this  type  usually  have 
relatively  better  prognosis  [26,27].  Our  IHC  staining  demonstrated  that  SIRT1  expressed 
more  highly  in  large  cell  MB  and  classic  MB  than  that  in  nodular  MB,  indicating  the 
potential link of SIRT1 expression with the biological behavior and poor prognosis of MB. To Functional Foods in Health and Disease 2013; 3(5):154-165                                                    Page 161 of 165 
confirm this notion, it is necessary to suppress SIRT1 expression by RNAi. Our data showed 
the growth of UW228-3 cells transfected with SIRT1 siRNA was significantly suppressed, 
accompanied with remarkable G1 phase arrest and apoptosis, consistent with those conducted 
on human DAOY and D283MED MB cells [21]. UW228-3 cells used in current study are 
from a classic MB. Since all of them are sensitive to anti-SIRT1 treatments, it would be 
possible that inhibition of SIRT1 expression may be applicable to different MB subtypes and 
SIRT1 might be a potential molecular target in the adjuvant management of MB.   
Our previous data demonstrating anti-tumor activity of Res and present study regarding 
SIRT1 as a tumor promoter in MB promote us to explore the involvement of SIRT1 in roles 
of Res. At present, we showed Res can decrease the expression of SIRT1 in UW228-3 MB 
cells. Moreover, inhibiting the expression of SIRT1 by RNAi suppressed the cell proliferation, 
caused G1 arrest and trigged apoptotic cell death of MB cells. These above findings propose 
a possibility that Res play anti-MB roles by inhibiting expression of SIRT1. It is worthy of 
mentioning that Res is usually referred as the activator of SIRT1 [45], which deacetylate 
some  tumor  suppressor  such  as  p53,  FOXOs  and  Ku70  [46-48].  SIRT1-mediated 
deacetylation  of  p53(K382)  decreases  p53-mediated  apoptosis,  and  then  promotes  the 
survival of cells. Therefore, we propose a question whether the anti-MB activity of Res is 
associated with its effect on the catalytic activity of SIRT1. In present study, we detected the 
acetylation  of  p53,  the  well-known  substrate  of  SIRT1.  ICC  and  WB  data  shown  the 
acetylation of p53 at lysine 382 did not change significantly. Regarding other reports question 
Res as SIRT1 activator [49] and some function of Res is independent of SIRT1 [50]. We 
speculated that in MB cells, Res inhibits the proliferation and induces apoptosis in a SIRT1 
activity-independent manner, but mainly by suppress the expression of SIRT1.   
 
CONCLUSION: 
Collectively,  high  SIRT1  expression  might  boost  the  formation  of  medulloblastoma. 
Resveratrol,  a  safe  polyphenol  and  easy  to  intake  from  common  foods,  might  possess 
anti-medulloblastoma by regulation the expression but not the enzymatic activity of SIRT1. 
Suppressing expression of SIRT1 might be a potential in therapy of medulloblastoma. 
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